According to this research report, most pharma and biotech companies are developing therapeutics for hemophilia in collaboration with educational institutes.
The study analysed that the hemophilia pipeline comprises of 53 drug candidates in the pipeline in different stages of development for the treatment of hemophilia.
Explore Report Description at: www.psmarketresearch.com/market-an…ipeline-analysis
In September 2016, Roche in collaboration with Chugai Pharmaceutical Co.
Ltd. initiated a Phase III trial to evaluate the safety, pharmacokinetics and efficacy of prophylactic subcutaneous emicizumab in patients (aged 12 years) suffering from hemophilia A without factor VIII inhibitors.
Many drug candidates received USFDA designations namely Orphan, Fast Track or Breakthrough designations in their clinical stages for the treatment of hemophilia. In August 2016, Orphan Drug Designation was granted to Phase III drug candidate of Chugai Pharmaceuticals, by Ministry of Health, Labour and Welfare, Japan.
Explore Report Sample at: www.psmarketresearch.com/market-an…is/report-sample
Some of the key players developing drugs for the treatment of hemophilia include Sangamo BioSciences, Inc., Caisson Biotech, Inc., XL-protein GmbH, and others.
Category: Market Research Publishers and RetailersCompany profile: PS Market Research is a global market research and consulting company. We provide market research reports, industry reports, business intelligence and research based consulting services across a range of industries. With the help of our professional corporate relations with various companies, our market research offers the most accurate market forecasting. Our analysts and consultants interact with leading companies of the concerned domain to substantiate every single data presented in our pub ...
For more information: